13F Holdings
中文EN

AUPH Aurinia Pharmaceuticals Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1600620 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY21.0%
TTM net income YoY303.7%
TTM EPS YoY308.9%
Revenue 3-yr CAGR26.5%
Net income 3-yr CAGR—

Margins

Gross margin90.6%
Operating margin48.6%
Net margin97.7%
FCF margin—
EBITDA margin54.6%

Returns

ROE61.4%
ROA46.4%
ROIC (approx.)34.6%
Asset turnover0.48x

Leverage & solvency

Liabilities / assets20.4%
Debt / equity0.00x
Current ratio6.12x
Interest coverage40.36x

Cash quality & payout

Operating cash flow / net income0.56x
Accruals ratio20.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$283.06M$235.13M$175.51M$134.03M$45.60M
Cost of revenue$32.66M$28.25M$14.15M$5.66M$1.09M
Gross profit$250.39M$206.88M$161.37M$128.37M$44.51M
R&D expense$32.51M$20.79M$49.64M$44.99M$51.14M
SG&A expense$101.79M$172.03M$195.04M$196.37M$173.50M
Operating income$104.91M-$4.69M-$91.69M-$111.47M-$180.74M
Interest expense$4.33M$4.83M$2.77M$0$0
Pretax income$114.16M$7.45M-$77.47M-$106.35M-$180.21M
Income tax-$173.04M$1.70M$551,000$1.83M$760,000
Net income$287.20M$5.75M-$78.02M-$108.18M-$180.97M
EBITDA$124.36M$14.76M-$80.04M-$108.76M-$177.97M
EPS (basic)2.140.04-0.54-0.76-1.40
EPS (diluted)2.070.04-0.54-0.76-1.40
Weighted avg. shares (diluted)138.70M146.19M143.24M141.91M129.37M
Balance sheet
Cash & equivalents$80.21M$83.43M$48.76M$94.17M$231.90M
Inventory$45.69M$39.23M$39.70M$24.75M$19.33M
Current assets$491.97M$446.60M$424.80M$442.54M$513.32M
PP&E, net$2.11M$2.73M$3.35M$3.65M$4.42M
Intangibles$3.76M$4.36M$4.98M$6.42M$8.40M
Total assets$751.59M$550.64M$548.06M$470.86M$543.37M
Current liabilities$93.72M$97.76M$77.19M$46.11M$40.65M
Total liabilities$170.26M$173.17M$170.11M$65.42M$64.28M
Shareholders' equity$581.33M$377.48M$377.95M$405.44M$479.09M
Shares outstanding132.32M140.88M143.83M142.27M141.60M
Cash flow statement
Operating cash flow$135.66M$44.39M-$33.46M-$79.53M-$157.69M
Investing cash flow-$32.77M$39.26M-$6.71M-$60.63M-$103.87M
Financing cash flow-$106.11M-$49.09M-$5.13M$2.43M$221.11M
Depreciation & amortization$19.45M$19.45M$11.65M$2.71M$2.76M
Stock-based compensation$14.68M$31.60M$45.31M$32.30M$31.24M
Share buybacks$98.16M$40.24M$0$0—

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.